Q-Line Biotech IPO GMP & Allotment
Q-Line Biotech is a SME IPO with a price band of Rs 326.00 to Rs 343.00 that listed on 29 May 2026 at a listing gain of +31.78%. Track its full GMP history, subscription data and listing details here.
- IPO Price Band
- ₹326.00 - ₹343.00
- Lot Size
- 400 Shares
- Bidding Closes
- 25 May 2026
- Listing Date
- 29 May 2026
Q-Line Biotech IPO GMP Today & Key Takeaways
Q-Line Biotech IPO officially listed on 29 May 2026 at Rs 452.00, delivering a +31.78% listing gain compared to its issue price of Rs 343.00. Pre-listing, its final recorded Grey Market Premium (GMP) was ₹109.
| Key Metric | Figure | Status / Context |
|---|---|---|
| Current GMP | ₹109 | +31.78% vs upper band (26 May 2026) |
| Est. Listing Price | ₹452.00 | +31.78% Est. Listing Gain |
| Price Band | ₹326.00 - ₹343.00 | SME IPO |
| Retail Minimum Investment | ₹2,74,400 | 2 Lot (400 Shares) |
| Bidding Window | 21 May 2026 – 25 May 2026 | Listed |
| Allotment & Listing Dates | Allotment: 26 May 2026 | Listing: 29 May 2026 |
Complete IPO information
| IPO Open Date | 21 May 2026 |
|---|---|
| IPO Close Date | 25 May 2026 |
| IPO Price Band | ₹326.00 - ₹343.00 |
| Lot Size | 400 Shares |
| Current GMP | ₹109 |
| Estimated Listing Gain | +31.78% |
| Issue Size | - |
| Fresh Issue | - |
| Issue Type | SME |
| IPO Listing | NSE, BSE |
| Retail Quota | TBA |
| Registrar | TBA |
| Overall Subscription | 50.82x |
| Minimum Investment | ₹2,74,400 |
| DRHP Draft Prospectus | |
| RHP Draft Prospectus | - |
IPO Snapshot & Investor Takeaways
At the upper end of its price band, Q-Line Biotech is priced at ₹343 per share. With a minimum lot size of 400 shares, a retail investor applying for one lot would need approximately ₹2,74,400 to participate in this SME issue.
The latest recorded Grey Market Premium for Q-Line Biotech stands at ₹109, implying an estimated listing gain of around 31.78% over the issue price if it holds until listing. This is down ₹24 from its previously recorded level. GMP reflects informal grey-market sentiment rather than a guaranteed outcome, and can change at any point until the day of listing.
As of the latest update, Q-Line Biotech's IPO was subscribed 50.82x overall, with a category-wise breakdown of Retail 47.12x, QIB 25.34x.
SME IPOs list on the dedicated SME platform of BSE/NSE. They usually involve smaller issue sizes and a higher per-lot investment than Mainboard issues, with comparatively lower institutional participation.
IPO roadmap at a glance
| Event / Milestone | Scheduled Date | Status |
|---|---|---|
| Bidding Opens | 21 May 2026 | Completed |
| Bidding Closes | 25 May 2026 | Completed |
| Allotment | 26 May 2026 | Completed |
| Listing | 29 May 2026 | Completed |
Daily GMP status
| Date | GMP | Change | Gain |
|---|---|---|---|
| 26 May 2026 | ₹101.00 | -₹24.00 | 29.45% |
| 25 May 2026 | ₹125.00 | +₹14.50 | 36.44% |
| 20 May 2026 | ₹110.50 | - | 32.22% |
Application size breakdown
| Category | Lots | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 2 Lot | 800 | ₹2,74,400 |
| Retail Maximum | 2 Lot | 800 | ₹2,74,400 |
| S-HNI Minimum | 3 Lot | 1,200 | ₹4,11,600 |
| S-HNI Maximum | 7 Lot | 2,800 | ₹9,60,400 |
| B-HNI Minimum | 8 Lot | 3,200 | ₹10,97,600 |
Objects of the Issue & Official Documents
IPO Reservation
| Investor Category | Share Offered | Shares (%) |
|---|---|---|
| Anchor Investor | – Shares | -% |
| QIB (Ex. Anchor) | 29,69,200 Shares | 50% |
| NII Shares Offered | 8,91,600 Shares | 15% |
| Retail Shares Offered | 20,79,200 Shares | 35% |
Q-Line Biotech IPO Anchor Investors
| Particulars | Details |
|---|---|
| Anchor Bidding Date | 2026 |
| Anchor Investors List | |
| Shares Offered | [.] Shares |
| Anchor Size | [.] Cr. |
| Lock-in Period End Date 50% Shares (30 Days) | 2026 |
| Lock-in Period End Date 50% Shares (90 Days) | 2026 |
ಕ್ಯೂ-ಲೈನ್ ಬಯೋಟೆಕ್ IPO Dates
| Particular | Dates |
|---|---|
| IPO Open Date | 21 May 2026 |
| IPO Close Date | 25 May 2026 |
| Basis of Allotment | 26 May 2026 |
| Refunds | - |
| Credit to Demat Account | - |
| IPO Listing Date | 29 May 2026 |
Note: The timeline for ಕ್ಯೂ-ಲೈನ್ ಬಯೋಟೆಕ್ IPO is tentative and subject to change.
Promoters and Holding Pattern
The promoters of the company are Saurabh Garg, Amita Garg, Ayush Garg, Ajay Kumar Mahanty and Abhay Agrawal.
| Particular | Shares | % Share |
|---|---|---|
| Promoter Holding Pre Issue | 1,70,74,999 | 96.77% |
| Promoter Holding Post Issue | 2,33,28,199 | -% |
ಕ್ಯೂ-ಲೈನ್ ಬಯೋಟೆಕ್ Objects of the Issue & Utilisation of Proceeds
To Be Updated Soon
About Q-Line Biotech IPO
Since its incorporation in 2013, Q-Line Biotech has been involved in the healthcare and diagnostic industry. The firm is known for manufacturing and supplying In-Vitro Diagnostic (IVD) products, medical diagnostic equipment, reagents, rapid test kits, and pathology instruments. The firm has been known to offer high-quality products and services at an affordable price range.
Q-Line Biotech has over 15 years of experience in the diagnostic industry and has served 150+ national and international clients. Moreover, the company also has 12 years of experience in developing and manufacturing various products. Its product range includes haematology, POC testing, clinical chemistry, molecular diagnostics, rapid tests, ELISA, and special diagnostics.
ಕ್ಯೂ-ಲೈನ್ ಬಯೋಟೆಕ್ Company Financials
To Be Updated Soon
ಕ್ಯೂ-ಲೈನ್ ಬಯೋಟೆಕ್ Company Valuation – FY2026
To Be Updated Soon
ಕ್ಯೂ-ಲೈನ್ ಬಯೋಟೆಕ್ IPO Peer Group Comparison
To Be Updated Soon
IPO Lead Managers aka Merchant Bankers
- Hem Securities Ltd.
- Share India Capital Services Pvt. Ltd.
Compare Q-Line Biotech IPO with similar IPOs
Q-Line Biotech IPO FAQs
Comments
Share a useful question or insight about Q-Line Biotech.
Leave a comment
Your email address will not be published. All comments and replies are reviewed before appearing.
Loading comments...